Brain Tissue Transplant

A brain transplant is a medical procedure where brain tissue is moved from one person to another. This could be from a baby's brain or an adult's brain. It's a very complex surgery used in rare situations.

Procedure

What people who've had Brain Tissue Transplant report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Brain Tissue Transplant

Who It's For

A brain tissue transplant places living tissue or cells into a specific area of the brain to replace cells that disease has destroyed. Despite the popular phrase "brain transplant," it involves small amounts of tissue or cells, not a whole brain. It remains experimental and is available only through clinical trials, not as routine treatment. Almost all of the research involves Parkinson's disease, in which the brain gradually loses the nerve cells that make dopamine, a chemical messenger needed for smooth movement. The idea is to implant new dopamine-producing cells into the putamen, a deep brain region that depends on dopamine, so the brain can make its own supply again. Early studies in the 1980s and 1990s used tissue donated from terminated pregnancies. Current trials mostly use dopamine cells grown in a laboratory from stem cells, which can be made in large, quality-controlled batches. Trials have generally enrolled adults with moderately advanced Parkinson's whose medicines still help but have started causing problems such as wearing off or involuntary movements. People with significant memory or thinking problems have usually been excluded. Established alternatives include adjusting medication, pump-delivered medicines and deep brain stimulation, which uses implanted electrodes. Unlike those treatments, a cell transplant cannot be turned up, turned down or removed once in place.

Before the Procedure

Joining a trial involves a long screening process. Expect several visits for neurological examinations, rating scales that measure movement while on and off medication, memory and thinking tests, and a home diary of symptom fluctuations. An MRI scan maps the brain for surgical planning, and many trials also use a PET scan, a type of imaging that shows how much dopamine activity the brain has. For that scan, people are usually asked to pause their Parkinson's medicines for some hours beforehand. The study team reviews every medicine and existing health condition, partly because grafts from another person's cells require medicines that suppress the immune system afterward. Infections, diabetes, kidney problems and other conditions that could make those medicines riskier are part of the discussion. The consent process should explain the trial's purpose, what is unknown, how long follow-up lasts (often five years) and what happens if the treatment does not help.

During the Procedure

The cells are placed with stereotactic neurosurgery, a technique that uses brain imaging and precise coordinates to guide a thin needle, called a cannula, to the target. In recent trials the operation has been done under general anesthesia, so the person is asleep. The surgeon makes a small opening in the skull, called a burr hole, on each side of the head and deposits the cells at several points along the needle's path in each putamen. Some centers use MRI during the surgery to confirm placement, while others use a frame fixed to the head. For grafts made from donor or stem cells, the first doses of immune-suppressing medicine are usually given around the time of surgery.

Recovery & Aftercare

After surgery, people stay in the hospital for monitoring, and trial teams typically schedule a check about ten days later. Recovery from the operation itself is usually quicker than the wait for results. The new cells need to mature and connect with the surrounding brain, a process that experts expect to take many months and possibly years. Parkinson's medicines are typically continued and adjusted along the way. People who received donor or stem cells usually take immune-suppressing medicines for about a year, which in recent trials meant tacrolimus, a transplant anti-rejection drug, often with a low dose of a steroid. These medicines need regular blood tests and lower the body's defenses against infection, so a fever or other sign of infection during that time calls for a prompt call to the study team. Follow-up includes repeated examinations, MRI scans and PET scans for several years. It is still unproven whether the treatment works. Some early fetal tissue recipients improved for many years and a few stopped Parkinson's medicines, while others gained nothing. In small open-label stem cell studies, in which everyone knows they received the treatment, many participants' movement scores improved, and imaging showed the cells surviving and producing dopamine. Because these studies lacked comparison groups and placebo effects in Parkinson's can be strong, larger controlled trials are needed. The transplant aims to restore dopamine; it is not expected to slow the disease, and non-movement symptoms did not clearly improve.

Risks & Complications

The procedure combines the risks of brain surgery with those of long-term immune suppression. Surgical risks include bleeding inside the brain and seizures; each has occurred in recent trials, though rarely. Immune-suppressing medicines can cause infections, high blood sugar, low platelet counts and high potassium levels. In one stem cell trial, a participant died of a lung infection while on these medicines, and the researchers identified the immune suppression as the main source of risk. A major problem with fetal tissue was graft-induced dyskinesia, involuntary movements that continue even without Parkinson's medicine. In two placebo-controlled trials, 15% and 56% of recipients developed them, and some needed further brain surgery to control them. Those trials also showed no overall benefit compared with placebo surgery. The stem cell trials reported so far have not seen this complication, possibly because the cells are purified more carefully, but follow-up is still short. Stem cell products carry a theoretical risk that leftover immature cells could grow into a tumor. Trials screen for this with repeated MRI, and none has been reported. Over a decade or more, grafted cells can also develop some of the same disease changes as the person's own brain cells, which may limit how long benefits last.

Questions to Ask Your Doctor

  1. 1.Am I a reasonable candidate for a cell transplant trial, or would deep brain stimulation or a medication pump suit my situation better?
  2. 2.What kind of cells does this trial use, and will I need to take immune-suppressing medicines, and for how long?
  3. 3.What improvement have participants seen so far, and how long might it take before I notice any change?
  4. 4.Does this trial include a placebo or sham surgery group, and what happens if I do not benefit?
  5. 5.Would taking part affect my eligibility for other treatments or trials later?

Last reviewed • Oct 2026

Educational content, not medical advice.